DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic Nonsquamous Non-Small-Cell Lung Cancer Without Driver Mutations (US/EU)
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape & Forecast | G7 | 2021
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Biomarkers in Oncology | Access & Reimbursment | US | NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma | 2021
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is…
Non-Small-Cell Lung Cancer | Unmet Need | Metastatic nonsquamous NSCLC without driver mutations | US/EU5 | UNNEON0032-2021
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2021
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
